Harmony Biosciences Holdings, Inc. (HRMY): Results of Operations and Financial Condition
Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hrmy-20260804xex99d1.htm EX-99.1 Exhibit 99.1 Harmony Biosciences Announces Record Q2 2026 Re venue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Millio
How this was made
The 30-second read
Why it matters
Traders can update models for HRMY’s 2026 revenue trajectory using the reported WAKIX net product revenue, patient growth, and reiterated guidance range, while also repricing pipeline probability for BP-205 based on favorable Phase 1 SAD PK and tolerability and the stated next-step calendar.
Market read
A single filing combines a commercial beat (record WAKIX revenue and patient growth) with early pipeline de-risking (BP-205 SAD) and concrete FDA/clinical dates, creating a near-term repricing catalyst for HRMY.
What to watch
Guidance is reiterated rather than raised, so upside may be capped unless the market expected a higher WAKIX trajectory or stronger patient growth than reported.
Background
SEC Form 8-K Item 2.02 with Exhibit 99.1 covering Q2 2026 WAKIX results and new early clinical data for BP-205, plus regulatory and development milestones for pitolisant franchise assets.
Ticker impact
Harmony reported Q2 2026 WAKIX net revenue of $261.3M (+30% YoY), raised/maintained 2026 guidance, and disclosed Phase 1 BP-205 SAD data plus upcoming milestones.
Likely positive bias for HRMY as traders price both sustained WAKIX demand and incremental clinical de-risking for BP-205; magnitude depends on how the market values the BP-205 timeline versus guidance expectations.
The filing is a primary disclosure (8-K with exhibit) containing concrete financial datapoints (revenue, patient growth, guidance range) and specific clinical program updates (SAD topline, expected MAD in Q4, IND/Phase 1b in Q3, Phase 2 mid-2027, plus pitolisant regulatory milestones).
Market effects
Reinforces investor appetite for sleep-disorder pharma with both commercial traction (WAKIX) and progressing orexin pipeline assets.
No specific regional market mechanism beyond US-listed biotech sentiment.
Limited; clinical and FDA milestones are US-centric, though Teijin/Bioprojet partnerships are referenced.
Counterpoint
The BP-205 Phase 1 SAD data is early and may not translate into efficacy; stock reaction could fade if investors focus on longer-dated Phase 2/Phase 3 timelines.
Key entities
- companyHarmony Biosciences Holdings, Inc.
HRMY reported record Q2 2026 WAKIX revenue, reiterated 2026 guidance, and disclosed Phase 1 SAD data for BP-205 with upcoming clinical/regulatory milestones.
- productWAKIX (pitolisant)
Narcolepsy-related therapy; Q2 2026 net product revenue was $261.3M and guidance remains $1.0B to $1.04B for 2026.
- clinical_programBP-205 (orexin-2 agonist)
Phase 1 SAD topline data showed favorable PK and safety/tolerability; MAD expected Q4 2026, Phase 1b in Q3 2026, Phase 2 mid-2027.
- regulatory_programPitolisant GR (gastro-resistant)
FDA NDA accepted in July with target PDUFA April 1, 2027; enteric coating aimed at reducing GI side effects.
